Patents Assigned to Children's Hospital Medical Center
  • Patent number: 10821094
    Abstract: The invention provides methods of treating an allergic inflammatory condition characterized by inflammation of a squamous epithelium in a target tissue using alpha-1 proteinase inhibitors to replenish SPINK7 protein and/or SPINK7 anti-proteinase activity in the target tissue, and related methods and compositions.
    Type: Grant
    Filed: December 22, 2016
    Date of Patent: November 3, 2020
    Assignee: CHILDREN'S HOSPITAL MEDICAL CENTER
    Inventors: Nurit P. Azouz, Marc E. Rothenberg
  • Patent number: 10815296
    Abstract: Disclosed are drugs capable of inhibiting the complement pathway for use for treating hematopoietic stem cell transplant (HSCT) associated thrombotic microangiopathy (HSCT-TMA, also called TA-TMA) in a subject that has undergone an HSCT. Also disclosed are methods of using drugs capable of inhibiting the complement pathway for use for treating hematopoietic stem cell transplant (HSCT) associated thrombotic microangiopathy (HSCT-TMA) in a subject that has undergone an HSCT.
    Type: Grant
    Filed: September 16, 2014
    Date of Patent: October 27, 2020
    Assignee: Children's Hospital Medical Center
    Inventors: Sonata Jodele, Benjamin L. Laskin
  • Patent number: 10815526
    Abstract: Methods and compositions disclosed herein generally relate to methods of identifying, validating, and measuring clinically relevant, quantifiable biomarkers of diagnostic and therapeutic responses for blood, vascular, cardiac, and respiratory tract dysfunction, particularly as those responses relate to septic shock in pediatric patients. In particular, the invention relates to identifying one or more biomarkers associated with septic shock in pediatric patients, obtaining a sample from a pediatric patient having at least one indication of septic shock, then quantifying from the sample an amount of one or more of said biomarkers, wherein the level of said biomarker correlates with a predicted outcome.
    Type: Grant
    Filed: November 25, 2014
    Date of Patent: October 27, 2020
    Assignees: CHILDREN'S HOSPITAL MEDICAL CENTER, UNIVERSITY OF CINCINNATI
    Inventors: Christopher John Lindsell, Hector R. Wong
  • Patent number: 10816621
    Abstract: A magnetic resonance (MR) signal detector grid assembly adapted for detection of signals in a magnetic resonance imaging apparatus is disclosed. The MR signal detector grid assembly may include a non-resonant grid of a plurality of wire elements and a plurality of detector elements. At least one end of a selected wire element may be electrically attached to an end of at least one other selected wire element. At least one of the detector elements may be configured to detect an MR signal induced on a wire element in the non-resonant grid. The plurality of wire elements may be substantially in the same plane, and the plane may be warped into an arbitrary three-dimensional surface. The three-dimensional surface may have a shape that is cylindrical, partially cylindrical, and/or saddle-shaped. The plurality of wire elements may form a rectilinear grid, a hexagonal grid, a triangular grid, and/or a pseudo-random grid.
    Type: Grant
    Filed: June 21, 2018
    Date of Patent: October 27, 2020
    Assignee: CHILDREN'S HOSPITAL MEDICAL CENTER
    Inventors: Charles Lucian Dumoulin, Wolfgang Manfred Loew
  • Publication number: 20200308644
    Abstract: Diagnostic methods for assessing risk of or presence of inflammatory bowel disease in a patient based on glycosyltransferase or histo-blood group antigen signatures or a combination thereof. Also disclosed herein are prognostic methods for monitoring inflammatory bowel disease progression in a patient.
    Type: Application
    Filed: April 13, 2020
    Publication date: October 1, 2020
    Applicant: Children's Hospital Medical Center
    Inventors: Ardythe L. MORROW, Lee A. DENSON
  • Patent number: 10781425
    Abstract: The generation of complex organ tissues from human embryonic and pluripotent stem cells (PSCs) remains a major challenge for translational studies. It is shown that PSCs can be directed to differentiate into intestinal tissue in vitro by modulating the combinatorial activities of several signaling pathways in a step-wise fashion, effectively recapitulating in vivo fetal intestinal development. The resulting intestinal “organoids” were three-dimensional structures consisting of a polarized, columnar epithelium surrounded by mesenchyme that included a smooth muscle-like layer. The epithelium was patterned into crypt-like SOX9-positive proliferative zones and villus-like structures with all of the major functional cell types of the intestine. The culture system is used to demonstrate that expression of NEUROG3, a pro-endocrine transcription factor mutated in enteric anendocrinosis is sufficient to promote differentiation towards the enteroendocrine cell lineage.
    Type: Grant
    Filed: June 20, 2017
    Date of Patent: September 22, 2020
    Assignee: Children's Hospital Medical Center
    Inventors: James M. Wells, Aaron M. Zorn, Jason R. Spence, Noah F. Shroyer
  • Patent number: 10769242
    Abstract: A current system allows data-driven hypothesis generation to identify therapeutic candidates for a disease phenotype treatment by identifying drugs and clinical indications associated with lower occurrences of disease-associated phenotype(s) by a drug/drug class. A current system may include a pharmaceutical hierarchical ontology; a phenotype hierarchical ontology; a record database comprising clinical event records; a database mining engine; and a mapping engine. The database mining engine may iteratively progress through a portion of the pharmacological hierarchical ontology and phenotype hierarchical ontology to iteratively select pairs of cohort entries from each ontology; and for each pair of cohort entries, query the clinical record database for matching records.
    Type: Grant
    Filed: January 5, 2016
    Date of Patent: September 8, 2020
    Assignee: CHILDREN'S HOSPITAL MEDICAL CENTER
    Inventors: Bruce Aronow, Mayur Sarangdhar, Scott Carl Tabar, Anil Goud Jegga
  • Patent number: 10765725
    Abstract: Disclosed are methods of treating pain in a mammal, which may include the step of administering human growth hormone to a mammal in need thereof. The pain treated by the disclosed methods may be of a type caused by inflammation induced mechanical and/or thermal hypersensitivity, and may include, for example, a pain type resulting from one or more conditions selected from peripheral injury pain, post-operative pain, cutaneous inflammation, cutaneous incision, muscle incision, or chronic pain. Disease states in which the disclosed methods may be used include fibromyalgia, sickle cell anemia, epidermolysis bullosa, erythromelalgia, complex regional pain syndrome, or generalized muscle pain.
    Type: Grant
    Filed: November 5, 2018
    Date of Patent: September 8, 2020
    Assignee: Children's Hospital Medical Center
    Inventors: Michael P. Jankowski, Xiaohua Liu, John Barns Rose
  • Patent number: 10761099
    Abstract: Disclosed herein are methods for detecting protein expression in an individual diagnosed with cystic fibrosis. The methods, in certain aspects, include the steps of obtaining a sample from said individual and detecting expression in said sample of each protein of a protein set. The method may further include the step of determining expression level of one or more proteins of the protein set. The disclosed methods may be used to predict one or more clinical parameters in an individual having cystic fibrosis.
    Type: Grant
    Filed: March 21, 2018
    Date of Patent: September 1, 2020
    Assignee: Children's Hospital Medical Center
    Inventors: Assem Ziady, Rhonda Szczesniak, John Clancy, Cole Brokamp
  • Patent number: 10751387
    Abstract: The instant disclosure relates to methods and compositions for the treatment of Gaucher disease, particularly type II and III neuronopathic Gaucher disease (nGD). The methods include the step of administering to an individual in need thereof an effective amount of a ryanodine receptor inhibitor or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: April 26, 2017
    Date of Patent: August 25, 2020
    Assignee: Children's Hospital Medical Center
    Inventors: Ying Sun, Benjamin Liou
  • Publication number: 20200255860
    Abstract: A strong insulator fragment from foamy virus, which can be used to insulate expression of a transgene and reduce genotoxicity of integrating vectors comprising such. The insulator fragment can also be used in gene targeting constructs in gene editing.
    Type: Application
    Filed: September 18, 2018
    Publication date: August 13, 2020
    Applicant: CHILDREN'S HOSPITAL MEDICAL CENTER
    Inventor: Punam MALIK
  • Publication number: 20200230106
    Abstract: Some embodiments of the invention include methods for treating an animal for disease or nerve damage, comprising administration of a composition comprising a myelination enhancing inhibitor to the animal. Other embodiments of the invention include methods for treating an animal for disease or nerve damage, comprising administration of a composition comprising an HDAC3 inhibitor to the animal. Still other embodiments of the invention include methods for treating an animal for MS or nerve damage, comprising administration of a composition comprising an HDAC3 inhibitor to the animal. Additional embodiments of the invention are also discussed herein.
    Type: Application
    Filed: August 8, 2018
    Publication date: July 23, 2020
    Applicant: CHILDREN'S HOSPITAL MEDICAL CENTER
    Inventors: Xuelian HE, Qing LU, Liguo ZHANG
  • Patent number: 10713440
    Abstract: A method for performing natural language processing of free text using domain-specific spreading activation. Embodiments of the present invention ontologize free text using an algorithm based on neurocognitive theory by simulating human recognition, semantic, and episodic memory approaches. Embodiments of the invention may be used to process clinical text for assignment of billing codes, analyze suicide notes or legal discovery materials, and for processing other collections of text. Further, embodiments of the invention may be used to more effectively search large databases, such as a database containing a large number of medical publications.
    Type: Grant
    Filed: October 2, 2018
    Date of Patent: July 14, 2020
    Assignee: Children's Hospital Medical Center
    Inventors: John P. Pestian, Pawel Matykiewicz, Wlodzislaw Duch, Tracy A. Glauser, Robert A. Kowatch, Jacqueline M. Grupp-Phelan, Michael Sorter
  • Publication number: 20200197395
    Abstract: Some embodiments of the invention include methods for treating an animal for cystic fibrosis comprising one or more administrations of one or more compositions comprising saracatinib. Other embodiments of the invention include treating an animal for cystic fibrosis comprising one or more administrations of one or more compositions comprising saracatinib, optionally a corrector of ?F508 CFTR, and optionally a potentiator of ?F508 CFTR. Still other embodiments of the invention include methods for treating a human with cystic fibrosis caused by the F508 deletion mutation in the cystic fibrosis transmembrane conductance regulator (CFTR), comprising one or more administrations of one or more compositions comprising saracatinib, and optionally VX770, VX809, or both. Additional embodiments of the invention are also discussed herein.
    Type: Application
    Filed: May 22, 2018
    Publication date: June 25, 2020
    Applicant: CHILDREN'S HOSPITAL MEDICAL CENTER
    Inventors: Anil Goud JEGGA, Anjaparavanda P. NAREN, Kavisha ARORA
  • Patent number: 10682396
    Abstract: A controlled release system includes surfactant protein D (SPD) and a carrier suitable for controlled release that can be polylactic-co-glycolic acid (PLGA). The system can be in the form of a nanoparticle. A pharmaceutical composition includes the system and a pharmaceutically acceptable carrier. Methods of treatment of a disease, disorder or condition associated with a decreased level of SPD in a subject, or for pulmonary delivery of SPD, include administering the pharmaceutical composition to a subject in need of such treatment.
    Type: Grant
    Filed: June 9, 2016
    Date of Patent: June 16, 2020
    Assignees: B.G. NEGEV TECHNOLOGIES AND APPLICATIONS LTD, CHILDREN'S HOSPITAL MEDICAL CENTER
    Inventors: Joseph Kost, Tamar Traitel, Riki Goldbart, Shani Attias, Paul Scot Kingma, Jeffrey A. Whitsett, Giora Enden
  • Patent number: 10675064
    Abstract: One or more techniques and/or systems are disclosed for a system for distraction osteogenesis of long bones. Selectively adjustable drive magnets disposed in the system can be used to distract the device. An external drive device generating a magnetic field may be used to rotate the drive in externally.
    Type: Grant
    Filed: November 9, 2017
    Date of Patent: June 9, 2020
    Assignees: CHILDREN'S HOSPITAL MEDICAL CENTER OF AKRON, AUSTEN BIOINNOVATION INSTITUTE IN AKRON
    Inventors: Stephen D. Fening, Todd Ritzman, John F. Zak
  • Patent number: 10675328
    Abstract: Disclosed are compositions and methods of treating a neurodegenerative disease in an individual. The methods disclose administration of an Integrin ?4?1, Very Late Antigen-4 positive neural precursor cell (“VLA4+ NPC”) transfected with a lentivirus overexpressing wild type GCase to an individual having a neurodegenerative disorder. The neurodegenerative disease may include lipid storage diseases, for example Gaucher disease, Parkinson's disease (PD), Dementia with Lewy bodies.
    Type: Grant
    Filed: February 14, 2018
    Date of Patent: June 9, 2020
    Assignee: Children's Hospital Medical Center
    Inventor: Ying Sun
  • Patent number: 10668078
    Abstract: Embodiments provided herein relate to methods and compositions for treating mesothelioma and/or a small cell lung cancer that express midkine.
    Type: Grant
    Filed: July 28, 2017
    Date of Patent: June 2, 2020
    Assignee: Children's Hospital Medical Center
    Inventors: Jeffrey A. Whitsett, Yutaka Maeda, Takuya Fukazawa
  • Patent number: 10668108
    Abstract: Disclosed are methods of treating or reducing the occurrence of a steatohepatitis disorder. The disorder may include, for example, NASH, parenteral nutrition associated liver disease (PNALD), or genetic forms of liver disease. The method may comprise the step of administering a composition comprising obeticholic acid to an individual in need thereof.
    Type: Grant
    Filed: November 3, 2017
    Date of Patent: June 2, 2020
    Assignee: CHILDREN'S HOSPITAL MEDICAL CENTER
    Inventors: Takanori Takebe, Rie Ouchi
  • Patent number: 10662476
    Abstract: Methods and compositions disclosed herein generally relate to methods of improving clinical and economic outcomes to address adverse effects related to anesthesia, analgesics, opioids, and inadequate pain relief. Embodiments of the invention relate to the association between genes, specific polymorphisms of genes, and non-genetic factors with inadequate pain relief and anesthesia-, analgesic, and/or opioid-related adverse effects. Embodiments of the invention can be used to determine and manage patient risk factors for development of adverse perioperative effects and can allow for personalized anesthesia and pain management for improvement of pain control and reduction of anesthesia-, analgesic-, and opioid-related adverse outcomes. These methods and compositions apply to non-surgical pain management with opioids.
    Type: Grant
    Filed: March 8, 2018
    Date of Patent: May 26, 2020
    Assignee: CHILDREN'S HOSPITAL MEDICAL CENTER
    Inventors: Senthilkumar Sadhasivam, Vidya Chidambaran, John McAuliffe, Kejian Zhang, Jaroslaw Meller, Cynthia A. Prows, Tsuyoshi Fukuda